Vectura Group PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
70,100.00
81,700.00
90,000.00
92,500.00
103,700.00
108,200
Total Accounts Receivable
5,000.00
8,700.00
19,600.00
30,800.00
34,100.00
35,300
Inventories
800.00
1,000.00
900.00
18,400.00
23,400.00
26,700
Other Current Assets
4,200.00
5,000.00
8,300.00
25,800.00
-
-
Total Current Assets
80,100.00
96,400.00
118,800.00
167,500.00
161,200.00
170,200
Net Property, Plant & Equipment
9,000.00
11,600.00
11,500.00
54,800.00
53,100.00
57,800
Total Investments and Advances
400.00
3,800.00
2,100.00
-
6,000.00
6,800
Intangible Assets
66,700.00
196,700.00
161,100.00
619,600.00
496,800.00
383,300
Other Assets
-
-
-
1,700.00
-
-
Total Assets
156,200.00
312,200.00
298,800.00
845,900.00
718,500.00
621,400
ST Debt & Current Portion LT Debt
-
-
-
-
200.00
Accounts Payable
3,800.00
2,300.00
2,500.00
22,400.00
23,700.00
Income Tax Payable
-
-
-
8,600.00
11,400.00
Other Current Liabilities
16,000.00
15,200.00
43,900.00
39,300.00
34,800.00
Total Current Liabilities
19,800.00
17,500.00
46,400.00
70,300.00
70,100.00
Long-Term Debt
-
-
-
-
3,900.00
Provision for Risks & Charges
-
-
-
9,400.00
6,800.00
Deferred Taxes
-
33,900.00
23,700.00
76,800.00
52,100.00
Other Liabilities
1,300.00
30,400.00
1,500.00
12,200.00
5,700.00
Total Liabilities
21,100.00
85,500.00
76,900.00
168,700.00
140,000.00
Common Equity (Total)
135,100.00
226,700.00
221,900.00
677,200.00
578,500.00
Total Shareholders' Equity
135,100.00
226,700.00
221,900.00
677,200.00
578,500.00
Total Equity
135,100.00
226,700.00
221,900.00
677,200.00
578,500.00
Liabilities & Shareholders' Equity
156,200.00
312,200.00
298,800.00
845,900.00
718,500.00

About Vectura Group

View Profile
Address
1 Prospect West
Chippenham Wiltshire SN14 6FH
United Kingdom
Employees -
Website http://vectura.com
Updated 07/08/2019
Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. It operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France.